837 related articles for article (PubMed ID: 7707627)
1. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
[TBL] [Abstract][Full Text] [Related]
2. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
Chaisson RE; Keruly J; Richman DD; Moore RD
Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
[TBL] [Abstract][Full Text] [Related]
3. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
Warnock AC; Rimland D
Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Torres RA; Barr M; Thorn M; Gregory G; Kiely S; Chanin E; Carlo C; Martin M; Thornton J
Am J Med; 1993 Dec; 95(6):573-83. PubMed ID: 8018144
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
Goldie SJ; Kaplan JE; Losina E; Weinstein MC; Paltiel AD; Seage GR; Craven DE; Kimmel AD; Zhang H; Cohen CJ; Freedberg KA
Arch Intern Med; 2002 Apr; 162(8):921-8. PubMed ID: 11966344
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.
Schneider MM; Hoepelman AI; Eeftinck Schattenkerk JK; Nielsen TL; van der Graaf Y; Frissen JP; van der Ende IM; Kolsters AF; Borleffs JC
N Engl J Med; 1992 Dec; 327(26):1836-41. PubMed ID: 1360145
[TBL] [Abstract][Full Text] [Related]
7. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.
Carr A; Tindall B; Penny R; Cooper DA
AIDS; 1992 Feb; 6(2):165-71. PubMed ID: 1558714
[TBL] [Abstract][Full Text] [Related]
8. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMI Study Group. Ligue Française de Prévention des Maladies Infectieuses.
May T; Beuscart C; Reynes J; Marchou B; Leclercq P; Borsa Lebas F; Saba J; Micoud M; Mouton Y; Canton P
J Acquir Immune Defic Syndr (1988); 1994 May; 7(5):457-62. PubMed ID: 8158539
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
Wordell CJ; Hauptman SP
Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
[TBL] [Abstract][Full Text] [Related]
10. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database.
Lim PL; Zhou J; Ditangco RA; Law MG; Sirisanthana T; Kumarasamy N; Chen YM; Phanuphak P; Lee CK; Saphonn V; Oka S; Zhang F; Choi JY; Pujari S; Kamarulzaman A; Li PC; Merati TP; Yunihastuti E; Messerschmidt L; Sungkanuparph S;
J Int AIDS Soc; 2012 Jan; 15(1):1. PubMed ID: 22281054
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus.
MMWR Recomm Rep; 1992 Apr; 41(RR-4):1-11. PubMed ID: 1348843
[TBL] [Abstract][Full Text] [Related]
12. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group.
Thea DM; Lambert G; Weedon J; Matheson PB; Abrams EJ; Bamji M; Straus WL; Thomas PA; Krasinski K; Heagarty M
Pediatrics; 1996 Jan; 97(1):59-64. PubMed ID: 8545225
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
Ioannidis JP; Cappelleri JC; Skolnik PR; Lau J; Sacks HS
Arch Intern Med; 1996 Jan; 156(2):177-88. PubMed ID: 8546551
[TBL] [Abstract][Full Text] [Related]
15. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
Girard PM; Landman R; Gaudebout C; Olivares R; Saimot AG; Jelazko P; Gaudebout C; Certain A; Boué F; Bouvet E
N Engl J Med; 1993 May; 328(21):1514-20. PubMed ID: 8479488
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
Bozzette SA; Finkelstein DM; Spector SA; Frame P; Powderly WG; He W; Phillips L; Craven D; van der Horst C; Feinberg J
N Engl J Med; 1995 Mar; 332(11):693-9. PubMed ID: 7854375
[TBL] [Abstract][Full Text] [Related]
17. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
18. Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients.
Freedberg KA; Hardy WD; Holzman RS; Tosteson AN; Craven DE
Med Decis Making; 1996; 16(1):29-35. PubMed ID: 8717596
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.
D'Egidio GE; Kravcik S; Cooper CL; Cameron DW; Fergusson DA; Angel JB
AIDS; 2007 Aug; 21(13):1711-5. PubMed ID: 17690568
[TBL] [Abstract][Full Text] [Related]
20. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
Mallolas J; Zamora L; Gatell JM; Miró JM; Vernet E; Valls ME; Soriano E; SanMiguel JG
AIDS; 1993 Jan; 7(1):59-64. PubMed ID: 8442918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]